Reneuron Share News (RENE)

UK AGM, EGM Calendar - Week Ahead

UK AGM, EGM Calendar - Week Ahead

UK AGM, EGM Calendar - Week Ahead

UK AGM, EGM Calendar - Week Ahead

DIRECTOR DEALINGS: ReNeuron Group Directors Buy Shares

Sector movers: Weak results, outlook from Glaxo sink pharma stocks

A slump in the share price of GlaxoSmithKline dragged the pharmaceuticals and biotechnology sector into the red on Wednesday as the drugmaker disappointed with a drop in quarterly sales and its full-year outlook. The company announced at midday that it has slashed its 2014 outlook as it reported a

ReNeuron well set after 'transformational' year

Stem cell treatment developer ReNeuron lost an increased £7.1m in a "transformational" year to end-March but still had plenty of cash in the bank as it moves into new cell manufacturing facility and files an investigational new drug (IND) application in the US early next year. The AIM-listed compa

UK MIDDAY BRIEFING: BOE Policy Makers Still Unanimous

LONDON (Alliance News) - Bank of England policymakers unanimously decided to leave the key interest rates and asset purchase programme unchanged at the monetary policy meeting held on June 4 and 5, the minutes of the meeting showed Wednesday.

All nine members of the Monetary Policy

ReNeuron Confident For Future Despite Loss As It Advances Therapies

LONDON (Alliance News) - ReNeuron Group PLC Wednesday expressed confidence in its future as it continued to develop its stem-cell therapies towards commercialisation, and it posted a widened loss in the year to end-March. The company posted a pretax loss of GBP7.8 million, widened from GBP7

UK MORNING BRIEFING: Zoopla Prices IPO As Markets Await Central Banks

LONDON (Alliance News) - UK shares have opened higher Wednesday, following a firm close on Wall Street and ahead of central bank announcements in the UK and US.

There was further IPO activity Wednesday, as property website Zoopla Property Group said it will price it

ReNeuron Says Stroke Disability Therapy Study Yielding "Encouraging" Results

LONDON (Alliance News) - Stem cell therapy company ReNeuron Group PLC Wednesday said that its PISCES study of its ReN001 stem cell therapy for stroke disability has continued to yield encouraging results. The company said that there was no cell-related or immunological adverse events report

ReNeuron seeks to expand board with new CEO

A new chief executive is being sought by AIM-listed stem cell specialist ReNeuron as it enters the next stage of its development. Current Chief Executive Michael Hunt will remain in the role until a replacement is recruited, when he will become Chief Financial Officer. Chairman Bryan Morton said:

ReNeuron Seeking New Chief Executive, Current To Become Financial Officer

LONDON (Alliance News) - ReNeuron Group PLC said Wednesday that it was appointing a new Chief Executive Officer to replace Michael Hunt, who will be moving into the role of Chief Financial Officer when a successor has been recruited. The company said that, as a result of the progress it has

ReNeuron leases building for relocation of business

AIM-listed ReNeuron has signed a deal with the Welsh government to lease a landmark building at Pencoed Technology Park, near Cardiff in South Wales. The stem cell therapy company explained that it will build a new state-of-the-art facility at Pencoed, to which it will relocate the business next ye

ReNeuron Leases New Research & Development Facility With Welsh Government

LONDON (Alliance News) - Stem cell therapy company ReNeuron Group PLC said Tuesday that it had signed an agreement with the Welsh Government to lease a new research and development facility at the Pencoed Technology Park near Cardiff, South Wales. ReNeuron expects to begin to relocate its o